Redeye: Camurus - A Swedish Biotech Success Story
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annual growth rate of 54% for 2020–2024 in the opioid use disorder market, a still strong outlook and a blockbuster pipeline.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/